Pasithea Therapeutics (KTTA) EPS (Weighted Average and Diluted) (2021 - 2024)
Historic EPS (Weighted Average and Diluted) for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$2.41.
- Pasithea Therapeutics' EPS (Weighted Average and Diluted) rose 4656.32% to -$2.41 in Q4 2024 from the same period last year, while for Dec 2024 it was -$12.69, marking a year-over-year increase of 31.42%. This contributed to the annual value of -$12.69 for FY2024, which is 39.56% down from last year.
- As of Q4 2024, Pasithea Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.41, which was up 4656.32% from -$2.87 recorded in Q3 2024.
- Over the past 5 years, Pasithea Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.06 during Q4 2021, and registered a low of -$4.51 during Q4 2023.
- For the 4-year period, Pasithea Therapeutics' EPS (Weighted Average and Diluted) averaged around -$1.78, with its median value being -$2.41 (2024).
- In the last 5 years, Pasithea Therapeutics' EPS (Weighted Average and Diluted) crashed by 1826944.92% in 2023 and then soared by 4656.32% in 2024.
- Over the past 4 years, Pasithea Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.06 in 2021, then crashed by 1492.1% to -$0.84 in 2022, then plummeted by 434.93% to -$4.51 in 2023, then soared by 46.56% to -$2.41 in 2024.
- Its last three reported values are -$2.41 in Q4 2024, -$2.87 for Q3 2024, and -$3.71 during Q2 2024.